Given the optimism around its obesity candidate, we believe investors should stay invested in Viking Therapeutics.

Eli Lilly (LLY) closed the latest trading day at $822.27, indicating a -0.22% change from the previous session's end. This change lagged the S&P 500's daily gain of 0.49%. Elsewhere, the Dow lost 0.2% ...

We recently published a list of the 11 Best Pharma Stocks to Buy According to Hedge Funds. In this article, we are going to ...

U.S. equities were mixed at midday as the markets weighed a better-than-expected report on inflation and more tariff news.

Eli Lilly (NYSE:LLY) has recently unveiled significant advancements across its product line, including promising results from ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli ...

Eli Lilly and Company’s LLY shares dipped almost 5% on Monday after rival Novo Nordisk NVO announced disappointing data from ...

Eli Lilly's stock fell 4.58% following weak trial results from Novo Nordisk’s obesity drug, shaking investor confidence in ...

The diabetes and weight loss drug market is heating up in 2025, with significant growth signs everywhere. According to a recent study from Research and Markets, industry growth is running at an ...

Stock splits tend to create a lot of buzz in the market, especially when some of the most prominent companies announce a ...

On Thursday, Jim Cramer, the host of Mad Money, discussed the recent turbulence in the stock market, pointing to the lack of ...

Shares of Eli Lilly & Co. LLY slid 4.73% to $869.58 Friday, on what proved to be an all-around positive trading session for ...